
    
      Post-marketing study to evaluate the effect of deferiprone and deferiprone 3-O-glucuronide on
      QTc prolongation in healthy volunteers after administration of a single therapeutic (33
      mg/kg) and supratherapeutic (50 mg/kg) oral dose of deferiprone and moxifloxacin (AveloxÂ®).
    
  